風險考慮因素:

  1. 本基金以主動方式管理及主要投資於公司股票價值被低估(即投資經理認為,與市場、同業及股票自身的過往表現相比,公司的股票價格較低)的廣泛多元化投資組合,該等公司遍佈世界各地,包括新興市場。
  2. 投資於本基金涉及風險,包括一般投資風險、股票市場風險、地理集中風險、與預託證券相關的風險、貨幣風險和剔除標準風險,並可能導致您損失部分或全部投資金額。
  3. 本基金可運用衍生工具作對沖及有效投資組合管理,因而涉及與衍生工具相關的風險。投資於衍生工具可能導致基金蒙受重大損失的風險。
  4. 本基金價值可以波動不定,並有可能大幅下跌。
  5. 投資者不應僅根據本[文件/網站]而投資於本基金 。

投資涉及風險。過往業績並非當前或將來的表現的可靠指標,亦不應作為選擇個別產品或策略的唯一考慮因素。

普徠仕(盧森堡)系列
環球價值股票基金
旨在透過其投資價值的增長,長遠而言提高其股份價值。
ISIN LU0859254822
基金單張
產品資料概要
SFDR 披露
2016年12月31日 - Sebastien Mallet, 基金經理,
We are cautiously optimistic about global equity markets and continue to concentrate on selecting companies with strong free cash flow generation, not yet fully appreciated by the market, and with the scope to increase shareholder returns. We are still finding areas of the global economy where fundamentally sound, well-run businesses face unwarranted investor scepticism.

概覽
策略
基金概要
以主動方式管理及主要投資於公司股票價值被低估(即投資經理認為,與市場、同業及股票自身的過往表現相比,公司的股票價格較低)的廣泛多元化投資組合,該等公司遍佈世界各地,包括新興市場。
表現(已扣除費用)

過往表現並非未來表現的可靠指標。

2016年12月31日 - Sebastien Mallet, 基金經理,
Global equities rose in December as optimism pervaded developed regions, and emerging markets recovered some of the losses from recent months. Stock selection in consumer staples contributed the most to relative performance, led by holdings in Flowers Foods and Philip Morris International. Information technology companies were also helpful, especially SUMCO Corporation. Conversely, health care stocks detracted from relative results, most notably Aetna. At the regional level, stock selection in Europe ex-UK boosted relative performance, while UK investments hindered relative returns.
2016年12月31日 - Sebastien Mallet, 基金經理,
Despite the recent rally in financials, we continue to have high conviction in the sector, which is both our largest absolute position and relative overweight in the portfolio. Even with valuations improving, financials are still broadly undervalued, particularly outside of the U.S. Within the sector, we favour high-quality capital markets and life insurance firms, as well as banks that are facing structural challenges but are improving their asset quality and balance sheet.

202309-3096143